IL-12 Half-Life Extension Engineering Service
Creative Biolabs offers end-to-end solutions to transform native interleukin-12 (IL-12) into a safe and effective targeted biologic. Our primary goal is to deliver an optimized lead candidate that is stable, highly targeted, and demonstrates confirmed bioactivity, allowing you to bypass the historical hurdles of systemic cytokine therapy and accelerate directly to application studies. We ensure that our engineered constructs achieve superior tumor microenvironment (TME) concentration, extended circulating half-life, and a significantly widened therapeutic window compared to first-generation approaches.
Background What We Can Offer Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
Next-Generation IL-12 Half-Life Extension Engineering
IL-12 is a potent master regulator that converts "cold" tumors into inflamed "hot" tumors by promoting T-cell and NK-cell activation and robust IFNγ production. Historically, its therapeutic use was severely limited by an extremely short half-life and dangerous systemic toxicity. The solution is precision engineering. This involves fusion or masking strategies that tether IL-12 to the tumor site (e.g., via extracellular matrix binding or tumor-associated antigen targeting) or ensure its conditional activation. This localized delivery is crucial for dramatically widening the therapeutic index, allowing for effective anti-tumor dosing while mitigating systemic side effects.
Premier Strategies for Targeted IL-12 Engineering
At Creative Biolabs, we specialize in the three most validated and effective approaches, each designed to overcome the limitations of systemic administration and restrict IL-12 activity to the tumor TME:
Fc-Fusion (Immunocytokine)
Fusing IL-12 to an engineered Fc domain provides half-life extension (FcRn engagement) and targeting via the variable region to a tumor-associated antigen (TAA), delivering synergistic IL-12 activity.
Albumin-Binding Domain (ABD) Fusion
The ABD binds to human serum albumin, extending the PK profile (approximately 21 days) via FcRn recycling. TME accumulation is enhanced actively through GP60/SPARC receptors overexpressed in the TME.
Conditional Activation (Prodrugs)
IL-12 is linked to a non-functional masking domain by a cleavable linker. This system is inert in circulation, maximizing the maximum tolerated dose (MTD), and is only activated by TME-specific enzymes, minimizing systemic toxicity.
Discover How Creative Biolabs Can Help Your Project - Request a Consultation Today
Workflow: Precision Engineering to Preclinical Lead
Our robust, five-step workflow is meticulously designed for clarity and efficiency, ensuring a rapid, scalable path from concept to a validated clinical candidate suitable for visualization as a professional flowchart.
Why Choose Us?
Creative Biolabs specializes in next-generation cytokine engineering, decoupling PK from IL-12 toxicity. Our FcRn and TME expertise ensures superior targeting: we maximize half-life via FcRn recycling and achieve enhanced tumor retention by exploiting albumin-binding mechanisms via GP60 and SPARC receptors. Our proprietary platform designs and screens custom cleavable prodrugs with specific protease-cleavable linkers, dramatically increasing the MTD. Furthermore, our validated linker technology, utilizing optimized linkers, ensures the IL-12 payload retains full, uncompromised biological activity.
Contact our scientific team today for a confidential consultation on your IL-12 project. Let's build the next generation of cancer immunotherapy together.
FAQs
Q:
Which IL-12 engineering approach is right for my project?
A:
The optimal strategy depends entirely on your specific TAA, disease target, and safety requirements. Fc-fusions are excellent for direct TAA targeting, ABD fusions offer long PK and general TME retention, and prodrugs maximize systemic safety.
Q:
How do your targeted constructs compare to simple PEGylated IL-12 for reducing toxicity?
A:
Simple PEGylation only extends the circulatory half-life; it does not prevent systemic toxicity. Our targeted constructs either actively concentrate the payload in the TME or prevent activation systemically.
Q:
Is there a risk of immunogenicity with the fusion proteins created by Creative Biolabs?
A:
We mitigate immunogenicity risks by using fully human components where possible (e.g., our optimized human ABD domain) and employing robust in silico de-immunization screening during the design phase.
Customer Review
-
Improved Tolerability
Using Creative Biolabs' service in our research has significantly improved the therapeutic index of our lead candidate. The toxicity reduction achieved via the ABD fusion was critical for moving from preclinical research to nonhuman primate studies. – Jn*Sith
-
Precise Activation
The cleavable linker optimization service facilitated tumor-selective activation in our latest immunocytokine. We confirmed MMP-9 specific cleavage kinetics in vitro that directly correlated with a massive reduction in systemic IFNγ release. – Dd*Wng
Related Services
To complement your IL-12 project and accelerate the path to the clinic, Creative Biolabs offers several highly complementary services:
Metabolite Identification Services
Creative Biolabs provides a rapid, high-throughput soft spot identification service using LC-MS and in vitro cross species comparison service to assess translational drug metabolism and toxicity.
Learn More →
Neoepitope Identification Service
Creative Biolabs' platform combines proprietary algorithms and genomics/sequencing for comprehensive neoantigen identification, facilitating the development of effective anti-tumor IO vaccines.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs is leading the charge in next-generation IL-12 engineering by solving the toxicity and half-life challenges that have historically plagued this potent cytokine. Ready to redefine your cytokine therapeutic? Contact our expert scientific team today for detailed information, project analysis, and a customized quote.
